Search

Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy is recommended for patients with muscle-invasive bladder cancer (MIBC). It has been shown that somatic deleterious mutations in ERCC2, gain-of-function mutations in ERBB2, and alterations in ATM, RB1, and FANCC are correlated with pathological response to NAC in MIBC. The objective of this study was to validate these genomic biomarkers in pretreatment transurethral resection material from an independent retrospective cohort of 165 patients with MIBC who subsequently underwent NAC and radical surgery. Patients with ypT0/Tis/Ta/T1N0 disease after surgery were defined as responders. Somatic deleterious mutations in ERCC2 were found in nine of 68 (13%) evaluable responders and two of 95 (2%) evaluable nonresponders (p = 0.009; FDR = 0.03). No correlation was observed between response and alterations in ERBB2 or in ATM, RB1, or FANCC alone or in combination. In an exploratory analysis, no additional genomic alterations discriminated between responders and nonresponders to NAC. No further associations were identified between the aforementioned biomarkers and pathological complete response (ypT0N0) after surgery. In conclusion, we observed a positive association between deleterious mutations in ERCC2 and pathological response to NAC, but not overall survival or recurrence-free survival. Other previously reported genomic biomarkers were not validated. Patient summary: It is currently unknown which patients will respond to chemotherapy before definitive surgery for bladder cancer. Previous studies described several gene mutations in bladder cancer that correlated with chemotherapy response. This study confirmed that patients with bladder cancer with a mutation in the ERCC2 gene often respond to chemotherapy.

Supplementary Figure 1 and Tables 1-8. Supplementary figure 1. Heatmap of common response, 2 and 6 hours after irradiation. Heatmap of the common response to 4 Gy irradiation in all 32 cell lines, adapted from the BRB-array tools time course plug-in output. Supplementary table 1 gives an overview of cell line characteristics. Supplementary table 2 describes the patient characteristics for the 34 patients in the validation cohort. Supplementary table 3 describes the references used for the definition of miR functions stated in table 1. Supplementary table 4 lists 1226 genes significantly correlated with radioresistance from a BRB time course plug-in analysis. Supplementary table 5 lists the genes in our p53 and DNA repair signatures. Supplementary table 6 lists the HNSCC EMT-scores for the 32 cell lines. Supplementary table 7 lists the 1189 genes in the HNSCC-EMT signature. Supplementary table 8 shows results of testing gene sets for reactive oxygen species, DNA repair, cell cycle phase and several means of cell death against the EMT gene set.

Supplementary Information. This file contains a text file with the interactions between miRs and mRNAs used for the analyses

Purpose: Predominant causes of head and neck cancer recurrence after radiotherapy are rapid repopulation, hypoxia, fraction of cancer stem cells, and intrinsic radioresistance. Currently, intrinsic radioresistance can only be assessed by ex vivo colony assays. Besides being time-consuming, colony assays do not identify causes of intrinsic resistance. We aimed to identify a biomarker for intrinsic radioresistance to be used before start of treatment and to reveal biologic processes that could be targeted to overcome intrinsic resistance.Experimental Design: We analyzed both microRNA and mRNA expression in a large panel of head and neck squamous cell carcinoma (HNSCC) cell lines. Expression was measured on both irradiated and unirradiated samples. Results were validated using modified cell lines and a series of patients with laryngeal cancer.Results: miRs, mRNAs, and gene sets that correlated with resistance could be identified from expression data of unirradiated cells. The presence of epithelial-to-mesenchymal transition (EMT) and low expression of miRs involved in the inhibition of EMT were important radioresistance determinants. This finding was validated in two independent cell line pairs, in which the induction of EMT reduced radiosensitivity. Moreover, low expression of the most important miR (miR-203) was shown to correlate with local disease recurrence after radiotherapy in a series of patients with laryngeal cancer.Conclusions: These findings indicate that EMT and low expression of EMT-inhibiting miRs, especially miR-203, measured in pretreatment material, causes intrinsic radioresistance of HNSCC, which could enable identification and treatment modification of radioresistant tumors. Clin Cancer Res; 21(24); 5630–8. ©2015 AACR.

PDF file - 56K, Supplementary Table S3 Read count, filtering and number of peaks.

PDF file - 101K, Supplementary Figure S5 Venn diagram, depicting the level of overlap of genes between 'proximity' and 'functionality' genes.

PDF file - 46K, Supplementary Table S2 Clinicopathological characteristics of the aromatase inhibitor cohort.

PDF file - 100K, Supplementary Figure S2 Overlap of peaks from the same ChIP-seq condition between tumors.

PDF file - 129K, Supplementary Table S4 Differential bound regions for ERalpha, H3K4me3 or H3K27me3 in 'poor' and 'good' outcome patients.

PDF file - 198K, Supplementary Figure S6 Differential response to aromatase inhibitors, using ChiA-PET associated genes and genes overlapping between proximity and ChIA-PET data.

PDF file - 192K, Supplementary Figure S4 Clustering heatmap analysis for ERalpha, H3K4me3 and H3K27me3.

PDF file - 35K, Supplementary Table S6 Gene lists of the ChIP-seq based classifiers for outcome after aromatase inhibitor treatment.

PDF file - 69K, Supplementary Table S7 Gene Ontology (GO) pathway enrichment for genes proximal to differentially enriched ERalpha, H3K4me3 and H3K27me3 binding events.

PDF file - 39K, Supplementary Table S5 QPCR primer sequences for 'good outcome' and 'poor outcome' enriched peaks for ERalpha, H3K4me3 and H3K27me3.

PDF file - 46K, Supplementary Table S8 Gene Ontology (GO) pathway overlap between ChIP-seq identified classifiers and pathways identified by Ellis et al., 2012 Nature.

PDF file - 55K, Supplementary Table S1 Patient and tumor characteristics of the discovery cohort.

PDF file - 43K, Supplementary Table S9 Univariate and multivariate analyses for TTP after treatment with first-line aromatase inhibitors.

PDF file - 169K, Supplementary Material and Methods Information on tumor samples, motif analysis, heatmaps, and genomic distributions of binding events, mRNA expression analysis, survival analysis and supplementary references.

PDF file - 110K, Supplementary Figure S3 Principal Component Analysis for all three ChIP-seq conditions.

Cancer-associated fibroblasts (CAFs) are abundantly present in the microenvironment of virtually all tumors and strongly impact tumor progression. Despite increasing insight into their function and heterogeneity, little is known regarding the origin of CAFs. Understanding the origin of CAF heterogeneity is needed to develop successful CAF-based targeted therapies. Through various transplantation studies in mice we determined that CAFs in both invasive lobular breast cancer and triple negative breast cancer originate from mammary tissue-resident normal fibroblasts (NFs). Single-cell transcriptomics, in vivo tracing and in vitro studies revealed the transition of CD26+ and CD26- NF populations into inflammatory CAFs (iCAFs) and myofibroblastic CAFs (myCAFs), respectively. In vitro functional assays showed that CD26+ NFs transition into pro-tumorigenic iCAFs which recruit myeloid cells in a CXCL12-dependent manner and enhance tumor cell invasion via matrix-metalloproteinase (MMP) activity. Together, our data show that CD26+ and CD26- NFs transform into distinct CAF subpopulations in breast cancer.

Genomic aberrations can be used to subtype breast cancer. In this study, we investigated DNA copy number (CN) profiles of 69 cases of male breast cancer (MBC) by array comparative genomic hybridization (aCGH) to detect recurrent gains and losses in comparison with female breast cancers (FBC). Further, we classified these profiles as BRCA1-like, BRCA2-like or non-BRCA-like profiles using previous classifiers derived from FBC, and correlated these profiles with pathological characteristics. We observed large CN gains on chromosome arms 1q, 5p, 8q, 10p, 16p, 17q, and chromosomes 20 and X. Large losses were seen on chromosomes/chromosome arms 1p, 6p, 8p, 9, 11q, 13, 14q, 16q, 17p, and 22. The pattern of gains and losses in estrogen receptor positive (ER+) MBC was largely similar to ER+ FBC, except for gains on chromosome X in MBC, which were uncommon in FBC. Out of 69 MBC patients, 15 patients (22%) had a BRCA2-like profile, of which 2 (3%) were also BRCA1-like. One patient (1%) was only BRCA1-like; the remaining 53 (77%) patients were classified as non-BRCA-like. BRCA2-like cases were more often p53 accumulated than non-BRCA-like cases (P = 0.014). In conclusion, the pattern of gains and losses in ER+ MBC was largely similar to that of its ER+ FBC counterpart, except for gains on chromosome X in MBC, which are uncommon in FBC. A significant proportion of MBC has a BRCA2-like aCGH profile, pointing to a potentially hereditary nature, and indicating that they could benefit from a drug regimen targeting BRCA defects as in FBC.

E-cadherin is a key regulator of epithelial cell–cell adhesion, the loss of which accelerates tumor growth and invasion. E-cadherin is also expressed in hematopoietic cells as well as epithelia. The function of hematopoietic E-cadherin is, however, mostly elusive. In this study, we explored the validity of mouse models to functionally investigate the role of hematopoietic E-cadherin in human hematopoiesis. We generated a hematopoietic-specific E-cadherin knockout mouse model. In mice, hematopoietic E-cadherin is predominantly expressed within the basophil lineage, the expression of which is dispensable for the generation of basophils. However, neither E-cadherin mRNA nor protein were detected in human basophils. In contrast, human hematopoietic E-cadherin marks the erythroid lineage. E-cadherin expression in hematopoiesis thereby revealed striking evolutionary differences between the basophil and erythroid cell lineage in humans and mice. This is remarkable as E-cadherin expression in epithelia is highly conserved among vertebrates including humans and mice. Our study therefore revealed that the mouse does not represent a suitable model to study the function of E-cadherin in human hematopoiesis and an alternative means to study the role of E-cadherin in human erythropoiesis needs to be developed.